|
|
|
|
|
|
|
18.10.25 - 22:21
|
Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results (Business Wire)
|
|
|
Conference Call October 20, 8:45am ESTQUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today provided preliminary revenue and financial results for the quarter ended September 30, 2025, and updated 2025 full-year revenue guidance.
Preliminary Third Quarter Financial Results (unaudited)
Total CHEMOSAT and HEPZATO KIT revenue of approximately $20.5 million
HEPZATO KIT revenue of $19.2 million
CHEMOSAT revenue of $1.3 million
Gross margins expected to be 87%
Net income of $0.8 million
Positive adjusted EBITDA of $5.3 million
Positive operating cashflow of approximately $4.8 million
As of September 30, 2025, the Company had approximately $88.9 million of cash, cash equivalents and short-term investments and no debt.
2025 Full Year Financial Guidance
Total CHEMOSAT and HEPZATO KIT revenue of $83 million to $85 million, reflecting an approximate 150% increase in treatment volume over 2024...
|
|
|
05.09.25 - 22:06
|
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to three individuals whose employment commenced in June 2025.
The grants resulted in the right to purchase 78,000 shares of the Company's common stock and are subject to the terms and conditions of the Company's 2023 Inducement Plan (“Plan”). The options were granted on August 29, 2025, the date the Compensation Committee approved the stock option included within the equity inducements and are subject to an exercise price equal to $11.02, the closing price of Delcath's common stock on August 29, 2025. One-third of the options will vest on the first anniversary of the grant date with the remaining two-thirds of the options vesting in equal monthly inst...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
09.05.25 - 23:36
|
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to eleven individuals whose employment commenced in March and April of 2025.
The grants resulted in the right to purchase 111,000 shares of the Company's common stock and are subject to the terms and conditions of the Company's 2023 Inducement Plan (“Plan”). The options were granted on April 30, 2025, the date the Compensation Committee approved the stock option included within the equity inducements and are subject to an exercise price equal to $12.04, the closing price of Delcath's common stock on April 30, 2025. One-third of the options will vest on the first anniversary of the grant date with the remaining two-thirds of the options vesting in equa...
|
|
|
|
|
|
|
08.05.25 - 13:36
|
Delcath Systems Reports First Quarter 2025 Results and Business Highlights (Business Wire)
|
|
|
Conference Call Today at 8:30 a.m. Eastern Time
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2025.
First Quarter 2025 Financial Results
Total revenue of $19.8 million, compared with $3.1 million in the first quarter of 2024
HEPZATO KIT™ revenue of $18.0 million, compared to $2.0 million in the first quarter of 2024
CHEMOSAT® revenue of $1.8 million, compared to $1.1 million in the first quarter of 2024
Gross margins of 86%, compared to 71% in the first quarter of 2024
Net income of $1.1 million, compared to a net loss of $11.1 million in the same quarter of 2024
Non-GAAP positive adjusted EBITDA in the first quarter of $7.6 million, compared to a loss of $7.3 million in the first quarter of 2024
Cash and investments of $58.9 million as of March ...
|
|
|
|
|
27.03.25 - 21:48
|
Beta Bionics Announces Board Appointment of Gerard Michel (GlobeNewswire EN)
|
|
|
IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (Nasdaq: DCTH), a commercial-stage interventional oncology company....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
